A group of researchers announced at the 22nd International AIDS Conference in Amsterdam last month that while their HIV-prevention trial is not yet finished, they believe the therapy will be a success. This isn’t the first research of its type to go exceptionally well; a trial was stopped early a few years ago, presumably because…
It was broadly provided details regarding February 25, 2016, that a man taking the HIV prevention to medicine, Truvada, gotten the infection in spite of being completely follower to the once-every day tranquilize routine. The news raised genuine worries among some with respect to how viable the procedure—known as HIV pre-presentation prophylaxis (PrEP)— really is…
No products in the cart.